Data / Drug companies / Umedica Laboratories USA Inc.
Umedica Laboratories USA Inc.: 52 products in the FDA NDC directory, labeler code 60290
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Umedica Laboratories USA Inc. (labeler code 60290) lists 52 products in the FDA National Drug Code Directory, covering 18 finished drugs by generic name. By type: 52 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on August 10, 2026.
The request: Watch Umedica Laboratories USA Inc. (FDA labeler code 60290): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 60290
- Products in commercial distribution
- 52
- Packages
- 164
- Finished drugs by generic name
- 18
- Prescription products
- 52
- Over the counter products
- 0
- Controlled substance products
- Schedule IV 1
- Flagged as original packager
- 3 of 3 products that carry the flag
- Started marketing in the last 12 months
- 45
- Earliest marketing start
- April 21, 2020
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 52 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 52 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Carbamazepine | 5 | 52 |
| Tadalafil | 4 | 54 |
| Celecoxib | 4 | 63 |
| Rosuvastatin calcium | 4 | 34 |
| Atorvastatin calcium | 4 | 59 |
| Oxcarbazepine | 3 | 46 |
| Sildenafil citrate | 3 | 24 |
| Varenicline | 3 | 11 |
| Olmesartan medoxomil and hydrochlorothiazide | 3 | 17 |
| Olmesartan medoxomil | 3 | 31 |
| Sacubitril and valsartan | 3 | 29 |
| Diclofenac sodium | 3 | 109 |
| Chlorthalidone | 2 | 42 |
| Ranolazine | 2 | 30 |
| Sertraline hydrochloride | 2 | 55 |
| Diclofenac potassium tablets | 2 | 6 |
| Diclofenac potassium | 1 | 42 |
| Zolpidem tartrate | 1 | 38 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 20 | 38.5% |
| Tablet, film coated | 15 | 28.8% |
| Capsule | 7 | 13.5% |
| Tablet, extended release | 5 | 9.6% |
| Tablet, delayed release | 3 | 5.8% |
| Powder, for solution | 1 | 1.9% |
| Kit | 1 | 1.9% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Sacubitril and Valsartan | 60290-087 | Tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| Sacubitril and Valsartan | 60290-086 | Tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| Sacubitril and Valsartan | 60290-085 | Tablet, film coated | Generic drugs (ANDA) | August 10, 2026 |
| Ranolazine | 60290-056 | Tablet, extended release | Generic drugs (ANDA) | August 10, 2026 |
| Ranolazine | 60290-055 | Tablet, extended release | Generic drugs (ANDA) | August 10, 2026 |
| Zolpidem Tartrate | 60290-089 | Capsule | Generic drugs (ANDA) | May 14, 2026 |
| Olmesartan Medoxomil and Hydrochlorothiazide | 60290-102 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Diclofenac Sodium | 60290-084 | Tablet, delayed release | Generic drugs (ANDA) | February 15, 2026 |
| Diclofenac Sodium | 60290-083 | Tablet, delayed release | Generic drugs (ANDA) | February 15, 2026 |
| Diclofenac Sodium | 60290-082 | Tablet, delayed release | Generic drugs (ANDA) | February 15, 2026 |
| Sildenafil citrate | 60290-079 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| Sertraline HCl | 60290-071 | Capsule | Generic drugs (ANDA) | February 15, 2026 |
| Sertraline HCl | 60290-070 | Capsule | Generic drugs (ANDA) | February 15, 2026 |
| Diclofenac potassium | 60290-061 | Powder, for solution | Generic drugs (ANDA) | February 15, 2026 |
| Atorvastatin calcium | 60290-042 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Atorvastatin calcium | 60290-041 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Atorvastatin calcium | 60290-040 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Atorvastatin calcium | 60290-039 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Tadalafil | 60290-030 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| Tadalafil | 60290-029 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| Tadalafil | 60290-028 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| Tadalafil | 60290-027 | Tablet, film coated | Generic drugs (ANDA) | February 15, 2026 |
| Olmesartan Medoxomil and Hydrochlorothiazide | 60290-026 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Olmesartan Medoxomil and Hydrochlorothiazide | 60290-025 | Tablet | Generic drugs (ANDA) | February 15, 2026 |
| Celecoxib | 60290-019 | Capsule | Generic drugs (ANDA) | February 15, 2026 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.